Announcement

Collapse
No announcement yet.

PLoS Pathog . Preclinical and clinical developments for combination treatment of influenza

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • PLoS Pathog . Preclinical and clinical developments for combination treatment of influenza


    PLoS Pathog


    . 2022 May 12;18(5):e1010481.
    doi: 10.1371/journal.ppat.1010481. eCollection 2022 May.
    Preclinical and clinical developments for combination treatment of influenza


    Paulina Koszalka 1 2 , Kanta Subbarao 1 3 , Mariana Baz 1 3



    Affiliations

    Abstract

    Antiviral drugs are an important measure of control for influenza in the population, particularly for those that are severely ill or hospitalised. The neuraminidase inhibitor (NAI) class of drugs, including oseltamivir, have been the standard of care (SOC) for severe influenza illness for many years. The approval of drugs with novel mechanisms of action, such as baloxavir marboxil, is important and broadens potential treatment options for combination therapy. The use of antiviral treatments in combination for influenza is of interest; one potential benefit of this treatment strategy is that the combination of drugs with different mechanisms of action may lower the selection of resistance due to treatment. In addition, combination therapy may become an important treatment option to improve patient outcomes in those with severe illness due to influenza or those that are immunocompromised. Clinical trials increasingly evaluate drug combinations in a range of patient cohorts. Here, we summarise preclinical and clinical advances in combination therapy for the treatment of influenza with reference to immunocompromised animal models and clinical data in hospitalised patient cohorts where available. There is a wide array of drug categories in development that have also been tested in combination. Therefore, in this review, we have included polymerase inhibitors, monoclonal antibodies (mAbs), host-targeted therapies, and adjunctive therapies. Combination treatment regimens should be carefully evaluated to determine whether they provide an added benefit relative to effectiveness of monotherapy and in a variety of patient cohorts, particularly, if there is a greater chance of an adverse outcome. Safe and effective treatment of influenza is important not only for seasonal influenza infection, but also if a pandemic strain was to emerge.


Working...
X